Skip to main content
SpringerLink
Log in

Use of Colistin in Critically Ill Patients

  • Chapter
  • First Online:
Polymyxin Antibiotics: From Laboratory Bench to Bedside

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1145))

Abstract

Due to lack of better therapeutic options, colistin use for extensively drug-resistant Gram-negative organisms was revived in the past two decades, including in patients in intensive-care units (ICU). There are multiple knowledge gaps pertaining to the clinical use and utility of colistin in critically-ill patients, but due to lack of options, it is used in these high risk patients. In this chapter, we critically review the various topics pertaining to colistin use in critically-ill patients, while highlighting the (lack of) controlled evidence supporting common current practices pertaining to colistin use by clinicians.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x

    Article  CAS  PubMed  Google Scholar 

  2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1–12. https://doi.org/10.1086/595011

    Article  PubMed  Google Scholar 

  3. Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40(9):1333–1341. CID35354 [pii] https://doi.org/10.1086/429323

    Article  CAS  PubMed  Google Scholar 

  4. Schwaber MJ, Carmeli Y (2008) Carbapenem-resistant enterobacteriaceae: a potential threat. JAMA 300 (24):2911–2913. https://doi.org/10.1001/jama.2008.896 300/24/2911 [pii]

  5. Peleg AY, Hooper DC (2010) Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362(19):1804–1813. https://doi.org/10.1056/NEJMra0904124 362/19/1804 [pii]

    Article  CAS  Google Scholar 

  6. Paterson DL (2006) Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 6 (5):486–490. S1471-4892(06)00136-6 [pii] https://doi.org/10.1016/j.coph.2006.07.001

    Article  CAS  PubMed  Google Scholar 

  7. Peterson LR (2008) A review of tigecycline–the first glycylcycline. Int J Antimicrob Agents 32(Suppl 4):S215–S222. https://doi.org/10.1016/S0924-8579(09)70005-6 [pii]

    Article  CAS  PubMed  Google Scholar 

  8. Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66(9):1963–1971. https://doi.org/10.1093/jac/dkr242 [pii]

    Article  CAS  Google Scholar 

  9. Cai Y, Wang R, Liang B, Bai N, Liu Y (2011) Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 55(3):1162–1172. https://doi.org/10.1128/AAC.01402-10 [pii]

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. FDA (2010) Drug safety communication - increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. FDA

    Google Scholar 

  11. Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, Campbell M, Khandker N, Lephart PR, Chopra T, Hayakawa K, Martin ET, Abreu-Lanfranco O, Dhar S, Kaye KS, Marchaim D (2012) Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 40(10):983–987. https://doi.org/10.1016/j.ajic.2011.12.014 S0196-6553(11)01336-8 [pii]

    Article  CAS  PubMed  Google Scholar 

  12. Gilad J, Carmeli Y (2008) Treatment options for multidrug-resistant Acinetobacter species. Drugs 68(2):165–189 doi:6823 [pii]

    Google Scholar 

  13. Liscio JL, Mahoney MV, Hirsch EB (2015) Ceftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant gram-negative bacterial infections. Int J Antimicrob Agents 46(3):266–271. https://doi.org/10.1016/j.ijantimicag.2015.05.003 S0924-8579(15)00203-4 [pii]

    Article  CAS  PubMed  Google Scholar 

  14. Falagas ME, Rafailidis PI (2008) Re-emergence of colistin in today’s world of multidrug-resistant organisms: personal perspectives. Expert Opin Investig Drugs 17(7):973–981. https://doi.org/10.1517/13543784.17.7.973

    Article  CAS  PubMed  Google Scholar 

  15. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55(7):3284–3294. https://doi.org/10.1128/AAC.01733-10 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Theuretzbacher U (2014) Product information for parenteral colistin varies substantially across Europe. J Antimicrob Chemother 69(7):1987–92. https://doi.org/10.1093/jac/dku064 [pii]

    Article  CAS  Google Scholar 

  17. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53 (8):3430–3436. https://doi.org/10.1128/AAC.01361-08 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Pogue JM, Marchaim D, Kaye D, Kaye KS (2011) Revisiting “older” antimicrobials in the era of multidrug resistance. Pharmacotherapy 31(9):912–921. https://doi.org/10.1592/phco.31.9.912

    Article  PubMed  Google Scholar 

  19. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS (2011) Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53(9):879–884. https://doi.org/10.1093/cid/cir611 [pii]

    Article  CAS  PubMed  Google Scholar 

  20. Nazer LH, Anabtawi N (2017) Optimizing colistin dosing: is a loading dose necessary? Am J Health Syst Pharm 74(1):e9–e16. https://doi.org/10.2146/ajhp150876 74/1/e9 [pii]

    Article  PubMed  Google Scholar 

  21. Vardakas KZ, Rellos K, Triarides NA, Falagas ME (2016) Colistin loading dose: evaluation of the published pharmacokinetic and clinical data. Int J Antimicrob Agents 48(5):475–484. S0924-8579(16)30258-8 [pii] https://doi.org/10.1016/j.ijantimicag.2016.08.009

    Article  CAS  PubMed  Google Scholar 

  22. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54(12):1720–1726. https://doi.org/10.1093/cid/cis286 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A (2010) Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35(2):194–199. https://doi.org/10.1016/j.ijantimicag.2009.10.005 S0924-8579(09)00469-5 [pii]

    Article  CAS  PubMed  Google Scholar 

  24. Zaidi ST, Al Omran S, Al Aithan AS, Al Sultan M (2014) Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. J Clin Pharm Ther. https://doi.org/10.1111/jcpt.12138

    Article  CAS  PubMed  Google Scholar 

  25. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD (2014) Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis 58(1):139–141. https://doi.org/10.1093/cid/cit680 [pii]

    Article  PubMed  Google Scholar 

  26. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, Lev S, Leon P, Raskin M, Yahav D, Leibovici L (2010) Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 65(5):1019–1027. https://doi.org/10.1093/jac/dkq069 [pii]

    Article  CAS  Google Scholar 

  27. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L (2003) Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7(5):R78–R83. https://doi.org/10.1186/cc2358

    Article  PubMed  PubMed Central  Google Scholar 

  28. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME (2005) Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11(2):115–121. CLM1043 [pii] https://doi.org/10.1111/j.1469-0691.2004.01043.x

    Article  CAS  PubMed  Google Scholar 

  29. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M (2006) Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28(4):366–369. S0924-8579(06)00290-1 [pii] https://doi.org/10.1016/j.ijantimicag.2006.07.008

    Article  CAS  PubMed  Google Scholar 

  30. Yilmaz GR, Bastug AT, But A, Yildiz S, Yetkin MA, Kanyilmaz D, Akinci E, Bodur H (2013) Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens. J Infect Chemother 19(1):57–62. https://doi.org/10.1007/s10156-012-0451-2

    Article  CAS  PubMed  Google Scholar 

  31. Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31(8):1058–1065. https://doi.org/10.1007/s00134-005-2691-4

    Article  PubMed  Google Scholar 

  32. Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, Bodey GP, Raad II (2007) Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 51(6):1905–1911. AAC.01015-06 [pii] https://doi.org/10.1128/AAC.01015-06

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Martin ET, Tansek R, Collins V, Hayakawa K, Abreu-Lanfranco O, Chopra T, Lephart PR, Pogue JM, Kaye KS, Marchaim D (2013) The carbapenem-resistant Enterobacteriaceae score: a bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients. Am J Infect Control 41(2):180–182. https://doi.org/10.1016/j.ajic.2012.02.036 S0196-6553(12)00716-X [pii]

    Article  PubMed  Google Scholar 

  34. Livermore DM, Hill RL, Thomson H, Charlett A, Turton JF, Pike R, Patel BC, Manuel R, Gillespie S, Balakrishnan I, Barrett SP, Cumberland N, Twagira M (2010) Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents 35(1):19–24. https://doi.org/10.1016/j.ijantimicag.2009.09.014 S0924-8579(09)00437-3 [pii]

    Article  CAS  PubMed  Google Scholar 

  35. Yahav D, Farbman L, Leibovici L, Paul M (2012) Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 18(1):18–29. https://doi.org/10.1111/j.1469-0691.2011.03734.x

    Article  CAS  PubMed  Google Scholar 

  36. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y (2011) Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 52(7):848–855. https://doi.org/10.1093/cid/cir025 [pii]

    Article  PubMed  Google Scholar 

  37. Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, Gales AC, Venezia SN, Quinn JP, Nordmann P (2010) Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis 16(9):1349–1356. https://doi.org/10.3201/eid1609.091389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796. https://doi.org/10.1016/S1473-3099(13)70190-7 S1473-3099(13)70190-7 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  39. Livermore DM (2005) Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 56(4):611–614. dki291 [pii] https://doi.org/10.1093/jac/dki291

    Article  CAS  Google Scholar 

  40. Alvarez-Marin R, Lopez-Rojas R, Marquez JA, Gomez MJ, Molina J, Cisneros JM, Ortiz-Leyba C, Aznar J, Garnacho-Montero J, Pachon J (2016) Colistin dosage without loading dose is efficacious when treating Carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia caused by strains with high susceptibility to colistin. PLoS One 11(12):e0168468. https://doi.org/10.1371/journal.pone.0168468 PONE-D-16-24297 [pii]

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Roberts JA, Lipman J (2012) Editorial commentary: closing the loop--a colistin clinical study to confirm dosing recommendations from PK/PD modeling. Clin Infect Dis 54(12):1727–1729. https://doi.org/10.1093/cid/cis311 [pii]

    Article  CAS  PubMed  Google Scholar 

  42. Sorli L, Luque S, Segura C, Campillo N, Montero M, Esteve E, Herrera S, Benito N, Alvarez-Lerma F, Grau S, Horcajada JP (2017) Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis 17(1):11. https://doi.org/10.1186/s12879-016-2117-7 [pii]

  43. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55(7):943–950. https://doi.org/10.1093/cid/cis588 [pii]

    Article  CAS  PubMed  Google Scholar 

  44. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25(1):11–25. S0924-8579(04)00365-6 [pii] https://doi.org/10.1016/j.ijantimicag.2004.10.001

    Article  PubMed  CAS  Google Scholar 

  45. Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, Doganay M (2012) Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 18(6):872–877. https://doi.org/10.1007/s10156-012-0430-7

    Article  CAS  PubMed  Google Scholar 

  46. Benattar YD, Omar M, Zusman O, Yahav D, Zak-Doron Y, Altunin S, Elbaz M, Daitch V, Granot M, Leibovici L, Paul M (2016) The effectiveness and safety of high-dose colistin: prospective cohort study. Clin Infect Dis 63(12):1605–1612. ciw684 [pii] https://doi.org/10.1093/cid/ciw684

    Article  CAS  PubMed  Google Scholar 

  47. Breakpoint tables for interpretation of mics and zone diameters (2011) Eucast - European Committee on Antimicrobial Susceptibility Testing

    Google Scholar 

  48. Performance standards for antimibrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100-S19 (2009). CLSI, Wayne, PA

    Google Scholar 

  49. Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, Endimiani A, Navon-Venezia S, Hothi J, Slim J, Blunden C, Shango M, Lephart PR, Salimnia H, Reid D, Moshos J, Hafeez W, Bheemreddy S, Chen TY, Dhar S, Bonomo RA, Kaye KS (2011) Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 55(2):593–599. https://doi.org/10.1128/AAC.01020-10 [pii]

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A, Nanas S, Paniara O, Roussos C, Giamarellos-Bourboulis E, Routsi C, Zakynthinos SG (2007) Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med 33(9):1524–1532. https://doi.org/10.1007/s00134-007-0683-2

    Article  CAS  PubMed  Google Scholar 

  51. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, Kopterides P, Souli M, Armaganidis A, Giamarellou H (2007) Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 59(4):786–790. dkl562 [pii] https://doi.org/10.1093/jac/dkl562

    Article  CAS  Google Scholar 

  52. Falagas ME, Rafailidis PI, Matthaiou DK (2010) Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Updat 13(4–5):132–138. https://doi.org/10.1016/j.drup.2010.05.002 S1368-7646(10)00031-2 [pii]

    Article  CAS  PubMed  Google Scholar 

  53. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA (2009) Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53(9):3628–3634. https://doi.org/10.1128/AAC.00284-09 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, Samonis G, Falagas ME (2008) Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 36(3):807–811. https://doi.org/10.1097/CCM.0B013E3181652FAE 00003246-200803000-00021 [pii]

    Article  PubMed  Google Scholar 

  55. Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Voutsinas D, Themeli-Digalaki K, Tsakris A (2010) Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol 48(6):2271–2274. https://doi.org/10.1128/JCM.02301-09 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  56. Bogdanovich T, Adams-Haduch JM, Tian GB, Nguyen MH, Kwak EJ, Muto CA, Doi Y (2011) Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis 53(4):373–376. https://doi.org/10.1093/cid/cir401 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  57. Bogan C, Marchaim D (2013) The role of antimicrobial stewardship in curbing carbapenem resistance. Future Microbiol 8(8):979–991. https://doi.org/10.2217/fmb.13.73

    Article  CAS  PubMed  Google Scholar 

  58. Cai Y, Chai D, Wang R, Liang B, Bai N (2012) Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67(7):1607–1615. https://doi.org/10.1093/jac/dks084 [pii]

    Article  CAS  Google Scholar 

  59. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, 3rd, Forrest A, Bulitta JB, Tsuji BT (2010) Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30(12):1279–1291. https://doi.org/10.1592/phco.30.12.1279 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Kawanishi M, Abo H, Ozawa M, Uchiyama M, Shirakawa T, Suzuki S, Shima A, Yamashita A, Sekizuka T, Kato K, Kuroda M, Koike R, Kijima M (2017) Prevalence of colistin resistance gene mcr-1 and absence of mcr-2 in Escherichia coli isolated from healthy food-producing animals in Japan. Antimicrob Agents Chemother 61(1). e02057-16 [pii] https://doi.org/10.1128/AAC.02057-16 [pii]

  61. Meinersmann RJ, Ladely SR, Plumblee JR, Cook KL, Thacker E (2017) Prevalence of mcr-1 in the Cecal contents of food animals in the United States. Antimicrob Agents Chemother 61 (2). e02244-16 [pii] https://doi.org/10.1128/AAC.02244-16 [pii]

  62. Tascini C, Ferranti S, Messina F, Menichetti F (2000) In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 6(12):690–691 doi:clm169 [pii]

    Google Scholar 

  63. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H (2003) In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 15(3):235–238. https://doi.org/10.1179/joc.2003.15.3.235

    Article  CAS  PubMed  Google Scholar 

  64. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC (2003) Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47(3):905–909

    Article  PubMed  PubMed Central  Google Scholar 

  65. Tascini C, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, Menichetti F (2004) Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 16(3):282–287. https://doi.org/10.1179/joc.2004.16.3.282

    Article  CAS  PubMed  Google Scholar 

  66. Petersen PJ, Labthavikul P, Jones CH, Bradford PA (2006) In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 57(3):573–576. dki477 [pii] https://doi.org/10.1093/jac/dki477

    Article  CAS  Google Scholar 

  67. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO (2006) In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 27(3):224–228. S0924-8579(05)00331-6 [pii] https://doi.org/10.1016/j.ijantimicag.2005.10.012

    Article  CAS  PubMed  Google Scholar 

  68. Zhanel GG, Mayer M, Laing N, Adam HJ (2006) Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50(6):2228–2230. 50/6/2228 [pii] https://doi.org/10.1128/AAC.01620-05

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Biancofiore G, Tascini C, Bisa M, Gemignani G, Bindi ML, Leonildi A, Giannotti G, Menichetti F (2007) Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol 73(3):181–185 doi:R02064890 [pii]

    Google Scholar 

  70. Chitnis S, Chitnis V, Chitnis DS (2007) In vitro synergistic activity of colistin with aminoglycosides, beta-lactams and rifampin against multidrug-resistant gram-negative bacteria. J Chemother 19(2):226–229. https://doi.org/10.1179/joc.2007.19.2.226

    Article  CAS  PubMed  Google Scholar 

  71. Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, Wang LR, Ko WC (2007) Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 27(11):1506–1511. https://doi.org/10.1592/phco.27.11.1506

    Article  CAS  PubMed  Google Scholar 

  72. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ (2007) In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60(2):317–322. dkm136 [pii] https://doi.org/10.1093/jac/dkm136

    Article  CAS  Google Scholar 

  73. Tan TY, Ng LS, Tan E, Huang G (2007) In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 60(2):421–423. dkm178 [pii] https://doi.org/10.1093/jac/dkm178

    Article  CAS  Google Scholar 

  74. Guzel CB, Gerceker AA (2008) In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy 54(2):147–151. https://doi.org/10.1159/000119741 [pii]

  75. Petrosillo N, Ioannidou E, Falagas ME (2008) Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 14(9):816–827. https://doi.org/10.1111/j.1469-0691.2008.02061.x CLM2061 [pii]

    Article  CAS  PubMed  Google Scholar 

  76. Tascini C, Urbani L, Biancofiore G, Rossolini GM, Leonildi A, Gemignani G, Bindi ML, Mugnaioli C, Filipponi F, Menichetti F (2008) Colistin in combination with rifampin and imipenem for treating a blaVIM-1 metallo-beta-lactamase-producing Enterobacter cloacae disseminated infection in a liver transplant patient. Minerva Anestesiol 74(1–2):47–49 doi:R02075090 [pii]

    Google Scholar 

  77. Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K (2009) Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63(3):534–542. https://doi.org/10.1093/jac/dkn530 [pii]

    Article  CAS  Google Scholar 

  78. Maisetta G, Mangoni ML, Esin S, Pichierri G, Capria AL, Brancatisano FL, Di Luca M, Barnini S, Barra D, Campa M, Batoni G (2009) In vitro bactericidal activity of the N-terminal fragment of the frog peptide esculentin-1b (Esc 1-18) in combination with conventional antibiotics against Stenotrophomonas maltophilia. Peptides 30(9):1622–1626. https://doi.org/10.1016/j.peptides.2009.06.004 S0196-9781(09)00222-8 [pii]

    Article  CAS  PubMed  Google Scholar 

  79. Principe L, D’Arezzo S, Capone A, Petrosillo N, Visca P (2009) In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 8:18. https://doi.org/10.1186/1476-0711-8-18 [pii]

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ (2009) Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 33(1):33–39. https://doi.org/10.1016/j.ijantimicag.2008.07.008 S0924-8579(08)00317-8 [pii]

    Article  CAS  PubMed  Google Scholar 

  81. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K (2009) Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother 53(5):2133–2135. https://doi.org/10.1128/AAC.01271-08 AAC.01271-08 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Dizbay M, Tozlu DK, Cirak MY, Isik Y, Ozdemir K, Arman D (2010) In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J Antibiot (Tokyo) 63(2):51–53.https://doi.org/10.1038/ja.2009.117 [pii]

    Article  PubMed  CAS  Google Scholar 

  83. Rodriguez CH, De Ambrosio A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, Radice M, Gutkind G, Vay C, Famiglietti A (2010) In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 4(3):164–167

    Article  CAS  PubMed  Google Scholar 

  84. Bercot B, Poirel L, Dortet L, Nordmann P (2011) In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae. J Antimicrob Chemother 66(10):2295–2297. doi:https://doi.org/10.1093/jac/dkr296 [pii]

  85. Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J (2011) Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis 11:109. https://doi.org/10.1186/1471-2334-11-109 [pii]

  86. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, Tsakris A (2011) Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 37(3):244–247. https://doi.org/10.1016/j.ijantimicag.2010.10.031 S0924-8579(10)00533-9 [pii]

    Article  CAS  PubMed  Google Scholar 

  87. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL (2005) Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41(8):1159–1166. CID35961 [pii] https://doi.org/10.1086/444500

    Article  CAS  PubMed  Google Scholar 

  88. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS (2014) Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58(2):654–663. https://doi.org/10.1128/AAC.01222-13 [pii]

    Article  PubMed  CAS  Google Scholar 

  89. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M (2013) Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57(10):5104–5111. https://doi.org/10.1128/AAC.01230-13 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE, Paterson DL, Nation RL, Li J (2011) Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 55(12):5685–5695. https://doi.org/10.1128/AAC.05298-11 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Molina J, Cordero E, Palomino J, Pachon J (2009) [Aminoglycosides and polymyxins]. Enferm Infecc Microbiol Clin 27(3):178–188. https://doi.org/10.1016/j.eimc.2009.02.001 S0213-005X(09)00098-6 [pii]

    Article  PubMed  Google Scholar 

  92. Marchaim D, Perez F, Lee J, Bheemreddy S, Hujer AM, Rudin S, Hayakawa K, Lephart PR, Blunden C, Shango M, Campbell ML, Varkey J, Manickam P, Patel D, Pogue JM, Chopra T, Martin ET, Dhar S, Bonomo RA, Kaye KS (2012) “Swimming in resistance”: co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa. Am J Infect Control 40(9):830–835. https://doi.org/10.1016/j.ajic.2011.10.013 S0196-6553(11)01267-3 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  93. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L (2018) Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18(4):391–400. https://doi.org/10.1016/S1473-3099(18)30099-9

    Article  CAS  PubMed  Google Scholar 

  94. Zavascki AP (2018) Colistin versus colistin plus meropenem for severe infections. Lancet Infect Dis 18(5):493–494. https://doi.org/10.1016/S1473-3099(18)30212-3

    Article  PubMed  Google Scholar 

  95. Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N (2018) Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother 73(1):22–32. https://doi.org/10.1093/jac/dkx368

    Article  CAS  PubMed  Google Scholar 

  96. Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J (2012) Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn Microbiol Infect Dis 74 (3):213–223. https://doi.org/10.1016/j.diagmicrobio.2012.07.010 S0732-8893(12)00309-4 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ (2012) Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38(11):1779–1786. https://doi.org/10.1007/s00134-012-2628-7

    Article  CAS  PubMed  Google Scholar 

  98. Linden PK, Paterson DL (2006) Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43Suppl 2:S89–S94. CID38720 [pii] https://doi.org/10.1086/504485

    Article  CAS  PubMed  Google Scholar 

  99. Beringer P (2001) The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 7(6):434–440

    Article  CAS  PubMed  Google Scholar 

  100. Hamer DH (2000) Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 162(1):328–330. https://doi.org/10.1164/ajrccm.162.1.9910071

    Article  CAS  PubMed  Google Scholar 

  101. Kwa AL, Loh C, Low JG, Kurup A, Tam VH (2005) Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41 (5):754–757. CID36576 [pii] https://doi.org/10.1086/432583

    Article  PubMed  Google Scholar 

  102. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME (2005) Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9(1):R53–R59. cc3020 [pii] https://doi.org/10.1186/cc3020

    Article  PubMed  PubMed Central  Google Scholar 

  103. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A (2006) The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 4(2):138–146. doi: 4/2/138 [pii]

    Google Scholar 

  104. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME (2008) Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 102(3):407–412. S0954-6111(07)00433-7 [pii] https://doi.org/10.1016/j.rmed.2007.10.011

    Article  PubMed  Google Scholar 

  105. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G (2010) Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 51(11):1238–1244. https://doi.org/10.1086/657242

    Article  CAS  PubMed  Google Scholar 

  106. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME (2010) Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 16(8):1230–1236. https://doi.org/10.1111/j.1469-0691.2009.03040.x CLM3040 [pii]

    Article  CAS  PubMed  Google Scholar 

  107. Ehrmann S, Roche-Campo F, Sferrazza Papa GF, Isabey D, Brochard L, Apiou-Sbirlea G (2013) Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med 39(6):1048–1056. https://doi.org/10.1007/s00134-013-2872-5

    Article  CAS  PubMed  Google Scholar 

  108. Lepine PA, Dumas A, Boulet LP (2017) Pulmonary eosinophilia from inhaled colistin. Chest 151(1):e1–e3. S0012-3692(16)52646-4 [pii] https://doi.org/10.1016/j.chest.2016.07.001

    Article  PubMed  Google Scholar 

  109. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC (2012) What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 54(5):670–680.https://doi.org/10.1093/cid/cir934 [pii]

    Article  CAS  PubMed  Google Scholar 

  110. Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK (2006) Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 58(5):1078–1081. dkl347 [pii] https://doi.org/10.1093/jac/dkl347

    Article  CAS  Google Scholar 

  111. Benifla M, Zucker G, Cohen A, Alkan M (2004) Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 54 (1):290–292. https://doi.org/10.1093/jac/dkh289 [pii]

    Article  CAS  Google Scholar 

  112. Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME (2005) Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect 50 (4):348–352. S0163445304000982 [pii] https://doi.org/10.1016/j.jinf.2004.05.008

    Article  Google Scholar 

  113. Bukhary Z, Mahmood W, Al-Khani A, Al-Abdely HM (2005) Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. Saudi Med J 26(4):656–658. doi:20040735 [pii]

    Google Scholar 

  114. Berlana D, Llop JM, Fort E, Badia MB, Jodar R (2005) Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 62(1):39–47

    Article  CAS  PubMed  Google Scholar 

  115. Khawcharoenporn T, Apisarnthanarak A, Mundy LM (2010) Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin Microbiol Infect 16(7):888–894. https://doi.org/10.1111/j.1469-0691.2009.03019.x CLM3019 [pii]

    Article  CAS  PubMed  Google Scholar 

  116. Fernandez-Viladrich P, Corbella X, Corral L, Tubau F, Mateu A (1999) Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 28(4):916–917. https://doi.org/10.1086/517243

    Article  CAS  PubMed  Google Scholar 

  117. Vasen W, Desmery P, Ilutovich S, Di Martino A (2000) Intrathecal use of colistin. J Clin Microbiol 38(9):3523

    CAS  PubMed  PubMed Central  Google Scholar 

  118. Yagmur R, Esen F (2006) Intrathecal colistin for treatment of Pseudomonas aeruginosa ventriculitis: report of a case with successful outcome. Crit Care 10(6):428. cc5088 [pii] https://doi.org/10.1186/cc5088

    Article  PubMed  PubMed Central  Google Scholar 

  119. Karaiskos I, Galani L, Baziaka F, Katsouda E, Ioannidis I, Andreou A, Paskalis H, Giamarellou H (2013) Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. Int J Antimicrob Agents 41(5):480–483. https://doi.org/10.1016/j.ijantimicag.2013.02.010 S0924-8579(13)00070-8 [pii]

    Article  CAS  PubMed  Google Scholar 

  120. Karaiskos I, Galani L, Baziaka F, Giamarellou H (2013) Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents 41(6):499–508. https://doi.org/10.1016/j.ijantimicag.2013.02.006 S0924-8579(13)00054-X [pii]

    Article  CAS  PubMed  Google Scholar 

  121. Bargiacchi O, Rossati A, Car P, Brustia D, Brondolo R, Rosa F, Garavelli PL, De Rosa FG (2014) Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review. Infection 42(5):801–809. https://doi.org/10.1007/s15010-014-0618-0

    Article  CAS  PubMed  Google Scholar 

  122. Ceylan B, Arslan F, Sipahi OR, Sunbul M, Ormen B, Hakyemez IN, Turunc T, Yildiz Y, Karsen H, Karagoz G, Tekin R, Hizarci B, Turhan V, Senol S, Oztoprak N, Yilmaz M, Ozdemir K, Mermer S, Kokoglu OF, Mert A (2017) Variables determining mortality in patients with Acinetobacter baumannii meningitis/ventriculitis treated with intrathecal colistin. Clin Neurol Neurosurg 153:43–49. S0303-8467(16)30432-2 [pii] https://doi.org/10.1016/j.clineuro.2016.12.006

    Article  PubMed  Google Scholar 

  123. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PM, Vroom MB, Dankert J, Kesecioglu J (2003) Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 362(9389):1011–1016. S0140-6736(03)14409-1 [pii] https://doi.org/10.1016/S0140-6736(03)14409-1

    Article  CAS  Google Scholar 

  124. Martin WJ (1964) Newer antimicrobial agents having current or potential clinical application. Med Clin North Am 48:255–292

    Article  CAS  PubMed  Google Scholar 

  125. Abele-Horn M, Dauber A, Bauernfeind A, Russwurm W, Seyfarth-Metzger I, Gleich P, Ruckdeschel G (1997) Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD). Intensive Care Med 23(2):187–195

    Article  CAS  PubMed  Google Scholar 

  126. Saidel-Odes L, Polachek H, Peled N, Riesenberg K, Schlaeffer F, Trabelsi Y, Eskira S, Yousef B, Smolykov R, Codish S, Borer A (2012) A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 33(1):14–19. https://doi.org/10.1086/663206

    Article  PubMed  Google Scholar 

  127. Agusti C, Pujol M, Argerich MJ, Ayats J, Badia M, Dominguez MA, Corbella X, Ariza J (2002) Short-term effect of the application of selective decontamination of the digestive tract on different body site reservoir ICU patients colonized by multi-resistant Acinetobacter baumannii. J Antimicrob Chemother 49(1):205–208

    Article  CAS  PubMed  Google Scholar 

  128. Bergmans DC, Bonten MJ, Gaillard CA, Paling JC, van der Geest S, van Tiel FH, Beysens AJ, de Leeuw PW, Stobberingh EE (2001) Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 164(3):382–388. https://doi.org/10.1164/ajrccm.164.3.2005003

    Article  CAS  PubMed  Google Scholar 

  129. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS, van der Hoeven JG, Pickkers P, Bogaers-Hofman D, van der Meer NJ, Bernards AT, Kuijper EJ, Joore JC, Leverstein-van Hall MA, Bindels AJ, Jansz AR, Wesselink RM, de Jongh BM, Dennesen PJ, van Asselt GJ, te Velde LF, Frenay IH, Kaasjager K, Bosch FH, van Iterson M, Thijsen SF, Kluge GH, Pauw W, de Vries JW, Kaan JA, Arends JP, Aarts LP, Sturm PD, Harinck HI, Voss A, Uijtendaal EV, Blok HE, Thieme Groen ES, Pouw ME, Kalkman CJ, Bonten MJ (2009) Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360(1):20–31. https://doi.org/10.1056/NEJMoa0800394 360/1/20 [pii]

    Article  CAS  Google Scholar 

  130. Godard J, Guillaume C, Reverdy ME, Bachmann P, Bui-Xuan B, Nageotte A, Motin J (1990) Intestinal decontamination in a polyvalent ICU. A double-blind study. Intensive Care Med 16(5):307–311

    Article  CAS  PubMed  Google Scholar 

  131. Gomez EC, Markowsky SJ, Rotschafer JC (1992) Selective decontamination of the digestive tract in intensive care patients: review and commentary. Ann Pharmacother 26(7–8):963–976

    Article  CAS  PubMed  Google Scholar 

  132. Hammond JM, Potgieter PD (1995) Is there a role for selective decontamination of the digestive tract in primarily infected patients in the ICU? Anaesth Intensive Care 23(2):168–174

    Article  CAS  PubMed  Google Scholar 

  133. Hammond JM, Potgieter PD (1995) Long-term effects of selective decontamination on antimicrobial resistance. Crit Care Med 23(4):637–645

    Article  CAS  PubMed  Google Scholar 

  134. Hammond JM, Potgieter PD, Saunders GL (1994) Selective decontamination of the digestive tract in multiple trauma patients--is there a role? Results of a prospective, double-blind, randomized trial. Crit Care Med 22(1):33–39

    Article  CAS  PubMed  Google Scholar 

  135. Hammond JM, Potgieter PD, Saunders GL, Forder AA (1992) Double-blind study of selective decontamination of the digestive tract in intensive care. Lancet 340(8810):5–9. doi:0140-6736(92)92422-C [pii]

    Google Scholar 

  136. Hartenauer U, Thulig B, Diemer W, Lawin P, Fegeler W, Kehrel R, Ritzerfeld W (1991) Effect of selective flora suppression on colonization, infection, and mortality in critically ill patients: a one-year, prospective consecutive study. Crit Care Med 19(4):463–473

    Article  CAS  PubMed  Google Scholar 

  137. Herruzo-Cabrera R, Garcia Gonzalez JI, Garcia-Magan P, del Rey-Calero J (1994) Nosocomial infection in a neonatal intensive care unit and its prevention with selective intestinal decolonization. A multivariant evaluation of infection reduction. Eur J Epidemiol 10(5):573–580

    Article  CAS  PubMed  Google Scholar 

  138. Melsen WG, de Smet AM, Kluytmans JA, Bonten MJ (2012) Selective decontamination of the oral and digestive tract in surgical versus non-surgical patients in intensive care in a cluster-randomized trial. Br J Surg 99(2):232–237. https://doi.org/10.1002/bjs.7703

    Article  CAS  PubMed  Google Scholar 

  139. Nardi G, Valentinis U, Proietti A, De Monte A, Di Silvestre A, Muzzi R, Peressutti R, Troncon MG, Giordano F (1993) Epidemiological impact of prolonged systematic use of topical SDD on bacterial colonization of the tracheobronchial tree and antibiotic resistance. A three year study. Intensive Care Med 19(5):273–278

    Article  CAS  PubMed  Google Scholar 

  140. Misset B, Kitzis MD, Conscience G, Goldstein F, Fourrier A, Carlet J (1994) Mechanisms of failure to decontaminate the gut with polymixin E, gentamicin and amphotericin B in patients in intensive care. Eur J Clin Microbiol Infect Dis 13(2):165–170

    Article  CAS  PubMed  Google Scholar 

  141. Houben AJ, Oostdijk EA, van der Voort PH, Monen JC, Bonten MJ, van der Bij AK (2014) Selective decontamination of the oropharynx and the digestive tract, and antimicrobial resistance: a 4 year ecological study in 38 intensive care units in the Netherlands. J Antimicrob Chemother 69(3):797–804. https://doi.org/10.1093/jac/dkt416 [pii]

    Article  CAS  Google Scholar 

  142. Buelow E, Gonzalez TB, Versluis D, Oostdijk EA, Ogilvie LA, van Mourik MS, Oosterink E, van Passel MW, Smidt H, D’Andrea MM, de Been M, Jones BV, Willems RJ, Bonten MJ, van Schaik W (2014) Effects of selective digestive decontamination (SDD) on the gut resistome. J Antimicrob Chemother. dku092 [pii] https://doi.org/10.1093/jac/dku092

    Article  CAS  Google Scholar 

  143. Kaiser AM, Schultsz C, Kruithof GJ, Debets-Ossenkopp Y, Vandenbroucke-Grauls C (2004) Carriage of resistant microorganisms in repatriates from foreign hospitals to The Netherlands. Clin Microbiol Infect 10(11):972–979. CLM1000 [pii] https://doi.org/10.1111/j.1469-0691.2004.01000.x

    Article  CAS  PubMed  Google Scholar 

  144. Bonten MJ, Waterer GW (2014) Antibiotics might do more than cause resistance. Am J Respir Crit Care Med 189(10):1157–1158. https://doi.org/10.1164/rccm.201404-0672ED

    Article  PubMed  Google Scholar 

  145. Halaby T, Al Naiemi N, Kluytmans J, van der Palen J, Vandenbroucke-Grauls CM (2013) Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother 57(7):3224–3229. https://doi.org/10.1128/AAC.02634-12 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Heininger A, Meyer E, Schwab F, Marschal M, Unertl K, Krueger WA (2006) Effects of long-term routine use of selective digestive decontamination on antimicrobial resistance. Intensive Care Med 32(10):1569–1576. https://doi.org/10.1007/s00134-006-0304-5

    Article  PubMed  Google Scholar 

  147. Oostdijk EA, Smits L, de Smet AM, Leverstein-van Hall MA, Kesecioglu J, Bonten MJ (2013) Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med 39(4):653–660. https://doi.org/10.1007/s00134-012-2761-3

    Article  CAS  PubMed  Google Scholar 

  148. Giua R, Pedone C, Cortese L, Antonelli Incalzi R (2014) Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature. Infection 42(1):199–202. https://doi.org/10.1007/s15010-013-0507-y

    Article  CAS  PubMed  Google Scholar 

  149. Pearman JW, Bailey M, Harper WE (1988) Comparison of the efficacy of “Trisdine” and kanamycin-colistin bladder instillations in reducing bacteriuria during intermittent catheterisation of patients with acute spinal cord trauma. Br J Urol 62(2):140–144

    Article  CAS  PubMed  Google Scholar 

  150. Waites KB, Canupp KC, Roper JF, Camp SM, Chen Y (2006) Evaluation of 3 methods of bladder irrigation to treat bacteriuria in persons with neurogenic bladder. J Spinal Cord Med 29(3):217–226

    Article  PubMed  PubMed Central  Google Scholar 

  151. Volkow-Fernandez P, Rodriguez CF, Cornejo-Juarez P (2012) Intravesical colistin irrigation to treat multidrug-resistant Acinetobacter baumannii urinary tract infection: a case report. J Med Case Rep 6(1):426. https://doi.org/10.1186/1752-1947-6-426 [pii]

  152. Maichuk YF (1991) Dexamethasone in the complex treatment of chlamydial conjunctivitis. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 68:83–93

    CAS  PubMed  Google Scholar 

  153. Matuska S, Rama P, Cavallero A, Paganoni G, Spinelli A, Brancato R (2006) Nocardia keratitis: a case report. Eur J Ophthalmol 16(1):164–167

    Article  CAS  PubMed  Google Scholar 

  154. Paksu MS, Paksu S, Karadag A, Sensoy G, Asilioglu N, Yildizdas D, Akyildiz BN, Kendirli T, Demirkol D, Akgun M, Alp E, Ciftci E, Guney AK, Murat N (2012) Old agent, new experience: colistin use in the paediatric intensive care unit--a multicentre study. Int J Antimicrob Agents 40(2):140–144. https://doi.org/10.1016/j.ijantimicag.2012.04.010 S0924-8579(12)00180-X [pii]

    Article  CAS  PubMed  Google Scholar 

  155. Logan LK (2012) Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis 55(6):852–859. https://doi.org/10.1093/cid/cis543 [pii]

    Article  CAS  PubMed  Google Scholar 

  156. Falagas ME, Vouloumanou EK, Rafailidis PI (2009) Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 33(6):503 e501–503 e513. https://doi.org/10.1016/j.ijantimicag.2008.10.021 S0924-8579(08)00550-5 [pii]

    Article  PubMed  CAS  Google Scholar 

  157. Karbuz A, Ozdemir H, Yaman A, Kocabas BA, Odek C, Guriz H, Aysev AD, Ciftci E, Kendirli T, Ates C, Ince E (2014) The use of colistin in critically ill children in a pediatric intensive care unit. Pediatr Infect Dis J 33(1):e19–e24. https://doi.org/10.1097/INF.0000000000000117 00006454-201401000-00012 [pii]

    Article  PubMed  Google Scholar 

  158. Alan S, Yildiz D, Erdeve O, Cakir U, Kahvecioglu D, Okulu E, Ates C, Atasay B, Arsan S (2014) Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii. Am J Perinatol 31(12):1079–1086. https://doi.org/10.1055/s-0034-1371361

    Article  PubMed  Google Scholar 

  159. Falagas ME, Sideri G, Korbila IP, Vouloumanou EK, Papadatos JH, Kafetzis DA (2010) Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatr Pulmonol 45(11):1135–1140. https://doi.org/10.1002/ppul.21302

    Article  PubMed  Google Scholar 

  160. Celik IH, Oguz SS, Demirel G, Erdeve O, Dilmen U (2012) Outcome of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa treated with aerosolized colistin in neonates: a retrospective chart review. Eur J Pediatr 171(2):311–316. https://doi.org/10.1007/s00431-011-1537-z

    Article  PubMed  Google Scholar 

  161. Falagas ME, Rafailidis PI (2007) When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. Shock 27(6):605–609. https://doi.org/10.1097/01.shk.0000246899.73315.cb 00024382-200706000-00003 [pii]

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Infection Control, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel

    Dror Marchaim

  2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Dror Marchaim

  3. Drexel University College of Medicine, Philadelphia, PA, USA

    Donald Kaye

  4. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA

    Keith S. Kaye

Authors
  1. Dror Marchaim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith S. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dror Marchaim .

Editor information

Editors and Affiliations

  1. Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Clayton Campus, Melbourne, VIC, Australia

    Jian Li

  2. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Melbourne, VIC, Australia

    Roger L. Nation

  3. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA

    Keith S. Kaye

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Marchaim, D., Kaye, D., Kaye, K.S. (2019). Use of Colistin in Critically Ill Patients. In: Li, J., Nation, R., Kaye, K. (eds) Polymyxin Antibiotics: From Laboratory Bench to Bedside. Advances in Experimental Medicine and Biology, vol 1145. Springer, Cham. https://doi.org/10.1007/978-3-030-16373-0_12

Download citation

Publish with us

Policies and ethics

Search

Navigation